Phenotyping [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2006-03-01 13:15 (6720 d 12:38 ago) – Posting: # 80
Views: 10,081

Hi Essar!

OK, risperidone shows polymorphism, so probably you will see a wide range of plasma concentrations in your study. If you perform phenotyping, you will have an explanation for high (PM) and low concentrations (EM), but it does not...

❝ "cancel out the inter-subject variability"

You are exactly right that...

❝ inter-subject variability will be taken care of by ANOVA

So phenotyping is not necessary; it only gives you insights on the distribution of poor and extensive metabolizers in your study (which you don't need in BE assessment).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
23,127 posts in 4,859 threads, 1,646 registered users;
37 visitors (0 registered, 37 guests [including 7 identified bots]).
Forum time: 02:53 CEST (Europe/Vienna)

No problem can stand the assault of sustained thinking.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz